Expression analysis of TRAF2‑ and NCK‑interacting protein kinase (TNIK) and phosphorylated TNIK in papillary thyroid carcinoma

Li,Jiali; Lan,Lili; Xu,Yuru; Liu,Shenghui; Liu,Meng; Hu,Guobin; Wu,Ganxun; Zhao,Yan; Shi,Jian; Wang,Jingtian; Sun,Yixin; Wang,Zhanlong; Zhao,Ruili

doi:10.3892/ol.2023.13896

Expression analysis of TRAF2‑ and NCK‑interacting protein kinase (TNIK) and phosphorylated TNIK in papillary thyroid carcinoma

Authors:
- Jiali Li
- Lili Lan
- Yuru Xu
- Shenghui Liu
- Meng Liu
- Guobin Hu
- Ganxun Wu
- Yan Zhao
- Jian Shi
- Jingtian Wang
- Yixin Sun
- Zhanlong Wang
- Ruili Zhao
View Affiliations

Affiliations: Research Center, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Otolaryngology Head and Neck Surgery, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: June 2, 2023 https://doi.org/10.3892/ol.2023.13896
Article Number: 310
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the expression of TRAF2‑ and NCK‑interacting kinase (TNIK) and the levels of the active form of TNIK, phosphorylated (p)‑TNIK, in papillary thyroid carcinoma (PTC), and to identify and compare the levels of TNIK and p‑TNIK among PTC, benign thyroid tumors and normal tissues. The levels of TNIK and p‑TNIK were examined by reverse transcription‑quantitative (RT‑q)PCR and immunohistochemical analysis (IHC) in PTC, benign thyroid tumors and normal tissues, and their association with clinicopathological features was evaluated. First, analysis of the Gene Expression Profiling Interactive Analysis and The Cancer Genome Atlas datasets suggested that the mRNA expression of TNIK was markedly increased in PTC tissues compared with that in normal tissues. RT‑qPCR analyses then indicated that the relative mRNA expression of TNIK in PTC tissues was 4.47±6.16, which was significantly higher than that in adjacent tissues 2.57±5.83. The IHC results suggested that the levels of TNIK and p‑TNIK in PTC tissues were markedly elevated compared with those in benign thyroid tumors and normal tissues. The levels of p‑TNIK in patients with PTC were significantly associated with extrathyroidal extension (χ²=4.199, P=0.040). Positive staining for TNIK was observed in 187 out of 202 (92.6%) cases in the cytoplasm, nucleus or cytomembrane of PTC cells. Among the 187 positive cases, cytoplasm expression was identified in 162 cases (86.6%), nuclear expression in 17 cases (9.1%) and cytomembrane expression in 8 cases (4.3%). Positive staining for p‑TNIK was observed in 179 out of 202 (88.6%) cases in the nuclei, cytoplasm or cytomembrane of PTC cells. In the 179 p‑TNIK‑positive cases, localization in the nuclei plus cytoplasm was identified in 142 cases (79.3%), nuclear localization in 9 cases (5.0%), presence in the cytoplasm in 21 cases (11.7%) and cytomembrane localization in 7 cases (3.9%). Both TNIK and p‑TNIK were upregulated in PTC tissues and p‑TNIK was significantly associated with extrathyroidal extension. It may act as a crucial oncogene to participate in PTC carcinogenesis and progression.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cancer Stat Facts, . Thyroid Cancer website. Available. https://seer.cancer.gov/statfacts/html/thyro.htmlSeptember 20–2018
3	Fagin JA and Wells SA Jr: Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 375:1054–1067. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zhao L, Pang P, Zang L, Luo Y, Wang F, Yang G, Du J, Wang X, Lyu Z, Dou J and Mu Y: Features and trends of thyroid cancer in patients with thyroidectomies in Beijing, China between 1994 and 2015: A retrospective study. BMJ Open. 9:e0233342019. View Article : Google Scholar : PubMed/NCBI
5	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
6	Cibas ES and Ali SZ: The 2017 bethesda system for reporting thyroid cytopathology. Thyroid. 27:1341–1346. 2017. View Article : Google Scholar : PubMed/NCBI
7	Jinih M, Foley N, Osho O, Houlihan L, Toor AA, Khan JZ, Achakzai AA and Redmond HP: BRAF^V600E mutation as a predictor of thyroid malignancy in indeterminate nodules: A systematic review and meta-analysis. Eur J Surg Oncol. 43:1219–1227. 2017. View Article : Google Scholar : PubMed/NCBI
8	Jia Y, Yu Y, Li X, Wei S, Zheng X, Yang X, Zhao J, Xia T and Gao M: Diagnostic value of B-RAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration: Systematic review and meta-analysis. Diagn Cytopathol. 42:94–101. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K and Miya A: An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 34:28–35. 2010. View Article : Google Scholar : PubMed/NCBI
10	Dong W, Horiuchi K, Tokumitsu H, Sakamoto A, Noguchi E, Ueda Y and Okamoto T: Time-varying pattern of mortality and recurrence from papillary thyroid cancer: Lessons from a long-term follow-up. Thyroid. 29:802–808. 2019. View Article : Google Scholar : PubMed/NCBI
11	Yu DH, Zhang X, Wang H, Zhang L, Chen H, Hu M, Dong Z, Zhu G, Qian Z, Fan J, et al: The essential role of TNIK gene amplification in gastric cancer growth. Oncogenesis. 2:e892014. View Article : Google Scholar : PubMed/NCBI
12	Torres-Ayuso P, An E, Nyswaner KM, Bensen RC, Ritt DA, Specht SI, Das S, Andresson T, Cachau RE, Liang RJ, et al: TNIK is a therapeutic target in lung squamous cell carcinoma and regulates FAK activation through merlin. Cancer Discov. 11:1411–1423. 2021. View Article : Google Scholar : PubMed/NCBI
13	Mahmoudi T, Li VS, Ng SS, Taouatas N, Vries RG, Mohammed S, Heck AJ and Clevers H: The kinase TNIK is an essential activator of Wnt target genes. EMBO J. 28:3329–3340. 2009. View Article : Google Scholar : PubMed/NCBI
14	Shitashige M, Satow R, Honda K, Ono M, Hirohashi S and Yamada T: Regulation of Wnt signaling by the nuclear pore complex. Gastroenterology. 134:1961–1971. 1971.e1–e4. 2008. View Article : Google Scholar : PubMed/NCBI
15	Gui J, Yang B, Wu J and Zhou X: Enormous influence of TNIK knockdown on intracellular signals and cell survival. Hum Cell. 24:121–126. 2011. View Article : Google Scholar : PubMed/NCBI
16	Shitashige M, Satow R, Jigami T, Aoki K, Honda K, Shibata T, Ono M, Hirohashi S and Yamada T: Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res. 70:5024–5033. 2010. View Article : Google Scholar : PubMed/NCBI
17	Jin J, Jung HY, Wang Y, Xie J, Yeom YI, Jang JJ and Lee KB: Nuclear expression of phosphorylated TRAF2- and NCK-interacting kinase in hepatocellular carcinoma is associated with poor prognosis. Pathol Res Pract. 210:621–627. 2014. View Article : Google Scholar : PubMed/NCBI
18	Takahashi H, Ishikawa T, Ishiguro M, Okazaki S, Mogushi K, Kobayashi H, Iida S, Mizushima H, Tanaka H, Uetake H and Sugihara K: Prognostic significance of Traf2- and Nck-interacting kinase (TNIK) in colorectal cancer. BMC Cancer. 15:7942015. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y, Jiang H, Qin M, Su X, Cao Z and Wang J: TNIK serves as a novel biomarker associated with poor prognosis in patients with pancreatic cancer. Tumour Biol. 37:1035–1040. 2016. View Article : Google Scholar : PubMed/NCBI
20	Fleuren EDG, Zhang L, Wu J and Daly RJ: The kinome ‘at large’ in cancer. Nat Rev Cancer. 16:83–98. 2016. View Article : Google Scholar : PubMed/NCBI
21	Masuda M, Uno Y, Ohbayashi N, Ohata H, Mimata A, Kukimoto-Niino M, Moriyama H, Kashimoto S, Inoue T, Goto N, et al: TNIK inhibition abrogates colorectal cancer stemness. Nat Commun. 7:125862016. View Article : Google Scholar : PubMed/NCBI
22	Sekita T, Yamada T, Kobayashi E, Yoshida A, Hirozane T, Kawai A, Uno Y, Moriyama H, Sawa M, Nagakawa Y, et al: Feasibility of targeting Traf2-and-Nck-interacting kinase in synovial sarcoma. Cancers (Basel). 12:12582020. View Article : Google Scholar : PubMed/NCBI
23	Sugano T, Masuda M, Takeshita F, Motoi N, Hirozane T, Goto N, Kashimoto S, Uno Y, Moriyama H, Sawa M, et al: Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. Br J Cancer. 124:228–236. 2021. View Article : Google Scholar : PubMed/NCBI
24	Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, et al: Direct conversion of osteosarcoma to adipocytes by targeting TNIK. JCI Insight. 6:e1372452021. View Article : Google Scholar : PubMed/NCBI
25	Lee RS, Zhang L, Berger A, Lawrence MG, Song J, Niranjan B, Davies RG, Lister NL, Sandhu SK, Rubin MA, et al: Characterization of the ERG-regulated kinome in prostate cancer identifies TNIK as a potential therapeutic target. Neoplasia. 21:389–400. 2019. View Article : Google Scholar : PubMed/NCBI
26	Sato K, Padgaonkar AA, Baker SJ, Cosenza SC, Rechkoblit O, Subbaiah DRCV, Domingo-Domenech J, Bartkowski A, Port ER, Aggarwal AK, et al: Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nat Commun. 12:46712021. View Article : Google Scholar : PubMed/NCBI
27	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
28	Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M and Saito Y: Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol. 77:413–418. 2000. View Article : Google Scholar : PubMed/NCBI
29	Joseph KR, Edirimanne S and Eslick GD: Multifocality as a prognostic factor in thyroid cancer: A meta-analysis. Int J Surg. 50:121–125. 2018. View Article : Google Scholar : PubMed/NCBI
30	Hanks SK, Quinn AM and Hunter T: The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science. 241:42–52. 1988. View Article : Google Scholar : PubMed/NCBI
31	Hunter T: Protein kinase classification. Methods Enzymol. 200:3–37. 1991. View Article : Google Scholar : PubMed/NCBI
32	Wissing J, Jänsch L, Nimtz M, Dieterich G, Hornberger R, Kéri G, Wehland J and Daub H: Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics. 6:537–547. 2007. View Article : Google Scholar : PubMed/NCBI
33	Liu R, Gao Q, Foltz SM, Fowles JS, Yao L, Wang JT, Cao S, Sun H, Wendl MC, Sethuraman S, et al: Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun. 12:25592021. View Article : Google Scholar : PubMed/NCBI
34	Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K and Takenoshita S: BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 22:6455–6457. 2003. View Article : Google Scholar : PubMed/NCBI
35	Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
36	Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI